- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01651702
Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations
Comparative Study of Two 3D Electroanatomical Mapping Systems for Ablations of Different Complex Arrhythmias
Study Overview
Detailed Description
Background:
Three dimensional anatomical mapping is an established method facilitating ablation of cardiac arrhythmias. It is nowadays an excepted method especially for complex arrhythmias such as atrial fibrillation and ventricular tachycardia.
The most commonly used systems are CARTO® System (Biosense Webster, Inc., Diamond Bar, CA, USA) and EnSite NavX™ (St. Jude Medical, Inc., St. Paul, MN, USA). These mapping systems have helped to decrease procedural complexity, procedure time, and improve safety. The EnSite NavX system uses impedance measurements between the individual catheter electrodes and the patches placed on the patient's chest and abdomen. The CARTO system utilizes magnetic location technology to provide accurate visualization of the magnet sensor-equipped catheter tip.
These two systems has been compared in only a few studies. Different results have been found in simple ablations versus more complex ablation of atrial fibrillation. Recent technical advances resulted in the development of new versions of both systems. Carto Express version allows quicker mapping and reconstruction of heart cavities and great vessels geometry as compared to previous versions of Carto XP. EnSite Velocity system incorporates more precise catheter visualization, and allows quicker mapping as compared to previous version of EnSite.
To the best of the investigators knowledge no studies have been performed for direct comparison of the newer versions of these two systems.
Study design Prospective single-center non-randomized open label comparison study. Primary objective Comparison of Carto Express system vs. EnSite Velocity system for ablation of complex arrhythmias.
End points:
- Procedure duration.
- Fluoroscopy time
- Procedure success -will be measured in terms of the 1-year recurrent arrhythmia rate Study population Patients planned for ablation of complex arrhythmia.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18- 80.
- Ability to sign informed consent.
History of one of the following arrhythmias requiring the use of 3D electroanatomical mapping:
- Symptomatic paroxysmal or persistent atrial fibrillation with failed treatment of at least two anti-arrhythmic drugs.
- Ischemic ventricular tachycardia necessitating ablation as per decision of electrophysiologist.
- Symptomatic atrial tachycardia after failed medical treatment.
- Symptomatic idiopathic ventricular tachycardia.
Exclusion Criteria:
- Unstable patients not allowing performing procedure more than 2 hours
- Patients planned for one of the two systems compared for whatever reason Ex. procedure planned with NAVX system Array Balloon).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Carto
Patients in whom Carto system will be used
|
Group of patients where Carto Express system will be used for electroanatomical mapping.
|
Active Comparator: Ensite
Patients in whom Ensite system will be used
|
Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure duration
Time Frame: Procedure duration - average expected 2.5 hours
|
Average procedure duration (needle to catheters withdrawal)
|
Procedure duration - average expected 2.5 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluoroscopy time
Time Frame: Procedures will be evaluated for the fluoro time, expected average 30 min
|
Average fluro time in each of groups.
|
Procedures will be evaluated for the fluoro time, expected average 30 min
|
Procedure success
Time Frame: Patients will be followed for one year for recurrency of arrhythmia
|
Recurrency of the arrhythmia assessed by blinded electrophysiologist
|
Patients will be followed for one year for recurrency of arrhythmia
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gregory Golovchiner, MD, Rabin Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0067-12-RMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arrhythmias
-
Medtronic BRCCompletedAtrial Fibrillation | Risk of Cardiac ArrhythmiasNetherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
-
Uri farkashCompletedEvaluation of Cardiac Arrhythmias in Hand Surgery Using Local Anesthesia With AdrenalineIsrael
-
Massachusetts General HospitalTerminated
-
The Leeds Teaching Hospitals NHS TrustCompletedArrhythmiasUnited Kingdom
-
Biosense Webster, Inc.Completed
-
Medtronic Cardiac Rhythm and Heart FailureCompletedCardiac ArrhythmiasAustria, France
-
Biosense Webster, Inc.CompletedArrhythmiasCzech Republic, Belgium
-
Instituto de Investigación Sanitaria Gregorio MarañónCatheter Robotics, Inc.Unknown
Clinical Trials on Carto
-
Military Institute of Medicine, PolandCompletedAtrial FibrillationPoland
-
The Cleveland ClinicBoston Scientific CorporationRecruitingParoxysmal Atrial FibrillationUnited States
-
Korea UniversityUnknownAtrial FibrillationKorea, Republic of
-
Shanghai Chest HospitalUnknown
-
Universitätsklinikum Hamburg-EppendorfBiosense Webster, Inc.CompletedParoxysmal Atrial FibrillationGermany
-
Biosense Webster, Inc.Melbourne Health; Royal Adelaide HospitalWithdrawn
-
Biosense Webster, Inc.Completed
-
Biosense Webster, Inc.CompletedAtrial Fibrillation | Paroxysmal AFUnited States
-
Shanghai Chest HospitalShandong University of Traditional Chinese Medicine; Department of Cardiology... and other collaboratorsNot yet recruitingPersistent Atrial FibrillationChina
-
Biosense Webster, Inc.CompletedAtrial FibrillationUnited States, Canada, Australia